Acumen Pharmaceuticals, Inc.

NasdaqGS ABOS

Acumen Pharmaceuticals, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -67.34 M

Acumen Pharmaceuticals, Inc. Free Cash Flow is USD -67.34 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -46.42% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Acumen Pharmaceuticals, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -45.99 M, a -65.80% change year over year.
Acumen Pharmaceuticals, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -27.74 M.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NasdaqGS: ABOS

Acumen Pharmaceuticals, Inc.

CEO	Mr. Daniel J. O'Connell M.B.A.
IPO Date	July 1, 2021
Location	United States
Headquarters	427 Park Street
Employees	51
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Key trends

Past 5 years